Head to head
PeterMD vs Maximus
What each one charges a month, which pharmacy each will name, and where each will treat you — read off their own sites, not their marketing.
Both sell compounded tirzepatide, where our ranking places PeterMD at #56 and Maximus at #64 — on the criteria we publish.
What each actually charges
A blank means that provider does not sell that compound at all. Prices are the real month-to-month figure, not a prepay or first-month rate.
| Compound | PE PeterMD | MA Maximus |
|---|---|---|
| Tirzepatide | $149 to start, $249/mo billed quarterly | $198/mo |
| Semaglutide | Doesn't sell it | $116/mo |
| Sermorelin | Doesn't sell it | $299.99/mo |
| Pharmacy named | Not disclosed | Not disclosed |
PeterMD checked August 2026; Maximus checked August 2026.
Who each one suits
Good fit if you want a specific two-state exclusion list (AL, ID) rather than a vague "some states" hedge.
The catch: PeterMD's own "$249 per month" tirzepatide price is billed quarterly, not monthly — the plan card discloses this on the same line ("billed quarterly"), but a reader skimming the featured "$149 to start" figure could easily miss that the real recurring charge lands as a single ~$747 payment every three months rather than a monthly line item.
Good fit if you want one company for all three, plus other hormone-optimization products.
The catch: The clearest finding: Maximus' own Terms of Use state that a multi-month "Program" participant who cancels mid-term "will remain responsible for fulfilling the payment obligations for the remainder of the commitment term" — signing up for the 6-month sermorelin plan to get the $199.99/mo headline rate means an early cancellation stops shipments, not the remaining bill. The same Terms state all fees are "non-refundable... regardless of your decision to terminate your usage." Separately, its own weight-loss page states three different prices for the same tirzepatide or semaglutide product without reconciling any of them. A live FDA warning letter is on record: Maximus Health, Inc. dba Maximus, MARCS-CMS 730095, June 8, 2026, for claims ("Clinically studied ingredients," "Proven to lose weight effectively") implying FDA evaluation, plus a false "FDA approved pharmacies" claim FDA directly rejects ("Compounding facilities... are not 'FDA-approved' or 'FDA-licensed' entities"). No fabricated-identity or deepfake pattern found — its named medical advisors are independently verifiable real clinicians, and complaints found are ordinary billing/communication friction.
Where each one will treat you
PeterMD
A real, specific exclusion list: its own tirzepatide page states, "Not available in these states: AL, ID."
Maximus
A real, specific exclusion list for weight loss ("all states but AL, MS, LA") and a narrower one for sermorelin ("all states except Alabama") — two different lists for two different products, neither page cross-referencing the other.
Ready to start with one?
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.